A new field of chemical biology planned which may provide funding is the synthesis of theranostics (theurapeutic + diagnostics).
The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for therapy of prostate cancer (PCa). A series of PSMA-X specific agents will be synthesized based on the chemical core of PSMA-617 (Schemes 1, 2).
Scheme 1. PSMA-X specific agents will be synthesized based on the chemical core of PSMA (Lys-Urea-Glu). Theragnostic molecules with diagnostic/therapeutic radionuclide 68Ga/ 177Lu and cytotoxic indotecan are also shown.
Scheme 2. Suggested synthetic procedure of PSMA analogues.
Also of targeted carrier-small molecules therapeutics. The carriers can include peptides as building blocks for the development of self-assembling.
